Live tape.Join the lounge

Research with context.

A clearer way to explore the market.

Create an account Contact the team

Market signals, research, watchlists, and alerts in one workspace.

Follow the signal.

Product Pricing FAQ

Data coverage Methodology Disclosures Contact

© 2026 Longbrunch. All rights reserved.

longbrunch/

NVO/Research

Fundamentals

Novo Nordisk A/S · Equity

Partial coverage

TradeShort termMedium termLong term

Financial health Growth Valuation Profitability Shareholder return

Financial health

2 current metrics

Total Assets2026-03-31: 559.22B kr
Total Liabilities2026-03-31: 356.16B kr

Historical trendData pending

Growth

4 current metrics

Eps2026-07-31: 4.18
Free Cash Flow2026-07-31: -12.04B kr
Net Income2026-03-31: 48.56B kr
Revenue2026-03-31: 96.82B kr

Historical trendData pending

Valuation

3 current metrics

Market Cap2026-07-31: 208.18B kr
Trailing Pe2026-07-31: 11.263159
Trailing P/E: 11.26

Historical trendData pending

Profitability

3 current metrics

Ebitda2026-07-31: 173.88B kr
Gross Profit2026-03-31: 83.23B kr
Operating Income2026-03-31: 59.62B kr

Historical trendData pending

Shareholder return

6 current metrics

Dividend Rate2026-07-31: 1.859
Dividend Yield2026-07-31: 3.95%
Ex Dividend Date2026-07-31: 2026-03-30
Payout Ratio2026-07-31: 44.47%
Trailing Annual Dividend Rate2026-07-31: 11.7
Trailing Annual Dividend Yield2026-07-31: 22.67%

Historical trendData pending

Financial evidence

Statement-level periods and line items live in the dedicated view.

Open Financial Statements →